NIKKEI 225
32,315.05 -363.57 (-1.11%) HANG SENG
17,466.90 -262.39 (-1.48%) CRUDE OIL
90.60 +0.92 (+1.03%) GOLD FUTURES
1,918.80 -17.80 (-0.92%) DOW
33,618.88 -388.00 (-1.14%) Bitcoin GBP
21,593.64 -135.00 (-0.62%)
Intercept Pharmaceuticals, Inc. (ICPT)
After hours:
| Previous close | 10.44 |
| Open | 18.39 |
| Bid | 18.71 x 40700 |
| Ask | 18.71 x 28000 |
| Day's range | 18.36 - 18.72 |
| 52-week range | 8.82 - 21.86 |
| Volume | |
| Avg. volume | 889,701 |
| Market cap | 781.754M |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today
Intercept is on track to be acquired by Alfasigma at a significant premium compared to recent prices.
- Motley Fool
Why CymaBay Therapeutics Stock Is Jumping Today
The continued momentum is a result of CymaBay's announcement yesterday of positive top-line results from a late-stage clinical study evaluating experimental drug seladelpar in treating primary biliary cholangitis (PBC), a rare chronic inflammatory liver disease. The great news for CymaBay, though, is that seladelpar appears to have a key advantage over those other PBC treatments. The results from the company's phase 3 study found that it significantly reduced itching, which is a major issue for many PBC patients.
- Zacks
Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
